Reversible Hepatotoxicity of Mirtazapine in a Patient with Major Depression Case Report

Please use this identifier to cite or link to this item: http://dspace.mediu.edu.my:8181/xmlui/handle/123456789/6058

Full metadata record

DC Field	Value	Language
dc.creator	Talha Dumlu	-
dc.creator	Fatih Canan	-
dc.creator	Gökhan Celbek	-
dc.creator	Adem Güngör	-
dc.creator	Yusuf Aydın	-
dc.date	2011	-
dc.date.accessioned	2013-05-30T14:10:43Z	-
dc.date.available	2013-05-30T14:10:43Z	-
dc.date.issued	2013-05-30	-
dc.identifier	http://www.turknoropsikiyatri.org/default.aspx?pfn=dergiOkur&iid=51&modulePage=article&dt=eft&aid=325	-
dc.identifier	http://www.doaj.org/doaj?func=openurl&genre=article&issn=13000667&date=2011&volume=48&issue=2&spage=162	-
dc.identifier.uri	http://koha.mediu.edu.my:8181/jspui/handle/123456789/6058	-
dc.description	Mirtazapine is a noradrenergic and specific serotonergic antidepressant that is approved for use in the treatment of major depression. It is generally well tolerated with some mild side effects such as drowsiness, excessive sedation, increased appetite, weight gain, and dry mouth. We present a case of 23 years old female depressive patient who developed abdominal pain and elevation of liver enzymes during treatment with mirtazapine and returned to normal after stopping the mirtazapine use. (Archives of Neuropsychiatry 2011; 48: 162-3)	-
dc.publisher	Galenos Yayicilik	-
dc.source	Nöropsikiyatri Arşivi	-
dc.subject	Hepatotoxicity	-
dc.subject	major depression	-
dc.subject	mirtazapine	-
dc.title	Reversible Hepatotoxicity of Mirtazapine in a Patient with Major Depression Case Report	-
Appears in Collections:	Health Sciences

Files in This Item:

There are no files associated with this item.

DSpace JSPUI